BIOCURE TECHNOLOGY INC. (1WH) - Total Liabilities
Based on the latest financial reports, BIOCURE TECHNOLOGY INC. (1WH) has total liabilities worth €435.01K EUR (≈ $508.58K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore BIOCURE TECHNOLOGY INC. long-term investment allocation to see how much of total assets are deployed in long-term investments.
BIOCURE TECHNOLOGY INC. - Total Liabilities Trend (2021–2025)
This chart illustrates how BIOCURE TECHNOLOGY INC.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see 1WH total assets.
BIOCURE TECHNOLOGY INC. Competitors by Total Liabilities
The table below lists competitors of BIOCURE TECHNOLOGY INC. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EJF Investments Ltd
LSE:EJFI
|
UK | GBX20.85 Million |
|
Lapidoth-Heletz Limited Partnership
TA:LPHL-L
|
Israel | ILA5.57 Million |
|
International Frontier Resources Corporation
V:IFR
|
Canada | CA$2.68 Million |
|
Rare Foods Australia Ltd
AU:RFA
|
Australia | AU$6.01 Million |
|
Ristia Bintang Mahkotasejati
JK:RBMS
|
Indonesia | Rp291.12 Billion |
|
Tearlach Resources Ltd
V:TEA
|
Canada | CA$1.02 Million |
|
Queste Communications Ltd
AU:QUE
|
Australia | AU$624.91K |
|
Argo Blockchain PLC ADR
NASDAQ:ARBK
|
USA | $9.83 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down BIOCURE TECHNOLOGY INC.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 1WH net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.10 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.28 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.22 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BIOCURE TECHNOLOGY INC.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BIOCURE TECHNOLOGY INC. (2021–2025)
The table below shows the annual total liabilities of BIOCURE TECHNOLOGY INC. from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €435.01K ≈ $508.58K |
-33.13% |
| 2024-12-31 | €650.57K ≈ $760.59K |
+74.30% |
| 2023-12-31 | €373.24K ≈ $436.36K |
-91.54% |
| 2022-12-31 | €4.41 Million ≈ $5.16 Million |
-11.87% |
| 2021-12-31 | €5.01 Million ≈ $5.85 Million |
-- |
About BIOCURE TECHNOLOGY INC.
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-ß for the treatment of multiple sclerosis; Ranibizumab for age-related vision loss; and Filgrastim for chemotherapy effects treatments. It also engages in the research and development of CAR T … Read more